NADAC acquisition cost data for STEGLATRO 15 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00006536403 | $10.40 | 2022-01-06 | Rx |
| 00006536406 | $10.40 | 2022-01-06 | Rx |
| 00006536407 | $10.40 | 2022-01-06 | Rx |
| 00006536403 | $10.40 | 2022-01-06 | Rx |
| 00006536406 | $10.40 | 2022-01-06 | Rx |
| 00006536407 | $10.40 | 2022-01-06 | Rx |
| 00006536403 | $10.40 | 2022-01-06 | Rx |
| 00006536406 | $10.40 | 2022-01-06 | Rx |
| 00006536407 | $10.40 | 2022-01-06 | Rx |
| 00006536403 | $10.40 | 2022-01-06 | Rx |
Generic: Ertugliflozin Pidolate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $5.5M | 15,126 | 5,427 | $9.32 |
| 2020 | $11.4M | 26,276 | 8,523 | $9.66 |
| 2021 | $15.0M | 31,930 | 10,149 | $10.14 |
| 2022 | $17.3M | 35,231 | 11,265 | $10.75 |
| 2023 | $18.2M | 36,893 | 11,552 | $11.44 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $5.1M | 9,692 | 2,614 |
| New York | $3.8M | 7,512 | 2,745 |
| New Jersey | $1.6M | 3,410 | 1,271 |
| Ohio | $710.5K | 1,452 | 378 |
| Florida | $592.6K | 1,606 | 578 |
| Texas | $558.5K | 915 | 276 |
| South Carolina | $510.8K | 978 | 255 |
| Kentucky | $494.8K | 1,091 | 322 |
| Indiana | $493.0K | 947 | 315 |
| Pennsylvania | $483.7K | 1,304 | 267 |
| New Mexico | $297.6K | 541 | 208 |
| Michigan | $289.9K | 654 | 215 |
| Oregon | $272.6K | 548 | 221 |
| Maryland | $215.3K | 486 | 192 |
| Georgia | $197.6K | 348 | 128 |
| Illinois | $196.3K | 439 | 163 |
| North Carolina | $192.5K | 487 | 175 |
| Virginia | $167.9K | 291 | 89 |
| Louisiana | $157.7K | 316 | 72 |
| Missouri | $147.6K | 276 | 73 |
| Tennessee | $140.5K | 353 | 95 |
| Utah | $138.1K | 266 | 74 |
| Minnesota | $132.2K | 398 | 109 |
| Connecticut | $114.2K | 203 | 59 |
| Arizona | $106.7K | 153 | 53 |
| Massachusetts | $81.6K | 189 | 54 |
| Alaska | $76.8K | 115 | 22 |
| Nevada | $76.1K | 142 | 84 |
| Colorado | $75.0K | 112 | 45 |
| Alabama | $74.5K | 147 | 39 |
| Oklahoma | $68.6K | 93 | 35 |
| Washington | $67.3K | 102 | 36 |
| Wisconsin | $63.9K | 118 | 48 |
| Kansas | $58.9K | 129 | 45 |
| West Virginia | $56.4K | 149 | 53 |
| Rhode Island | $53.6K | 140 | 40 |
| Arkansas | $44.9K | 90 | 28 |
| Hawaii | $41.9K | 84 | 54 |
| Puerto Rico | $32.0K | 76 | 28 |
| Nebraska | $30.0K | 70 | 22 |
| Mississippi | $25.1K | 43 | 14 |
| District of Columbia | $24.6K | 64 | 29 |
| New Hampshire | $24.0K | 53 | 16 |
| Wyoming | $23.5K | 44 | N/A |
| Idaho | $22.3K | 49 | N/A |
| North Dakota | $21.8K | 42 | N/A |
| Iowa | $19.1K | 19 | N/A |
| Vermont | $18.7K | 20 | N/A |
| Delaware | $17.5K | 22 | 12 |
| Montana | $14.4K | 31 | N/A |
| Maine | $13.2K | 37 | 13 |
| South Dakota | $12.8K | 16 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.